The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

van Zonneveld M., Flink H., Verhey E., Senturk H., Zeuzem S., Akarca U., ...More

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol.21, no.9, pp.1163-1171, 2005 (SCI-Expanded) identifier identifier identifier


Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.